STAT+: A Huntington’s researcher on the UniQure-FDA fray
A Huntington's researcher treads lightly into the UniQure-FDA fray, J&J wins approval for a first-of-its kind psoriasis pill, and more in today's Readout newsletter.
Health
FTC Tightens Antitrust Watch on Pharma as Patent Expiries Loom for Blockbuster Drugs Including Keytruda, Eliquis, Darzalex
Philadelphia: The U.S. Federal Trade Commission is on the lookout for anticompetitive practices in the pharmaceutical industry with a number of blockbuster drugs near the end of their patents, the…
Volar locking plate fixation tied to stable anatomical reduction in distal radius fractures with excellent functional recovery: study
Most frequent injuries of the Upper limb are a distal radius fracture (DRF). If they arent handled well, they might cause problems for a long time. There are several techniques…
Initiation of Menopausal Hormone therapy later in life tied to adverse cardiovascular outcomes: Study
Data published in Menopause show that women who start menopausal hormone therapy (HT) at age 65 years or older have a higher risk of ischemic heart disease and heart attack…
Clear Liquid Diet may Prevent Residual Gastric Volume in GLP-1 Users Before Endoscopy: JAMA
A recent study published in the Journal of the American Medical Association found that patients taking glucagon-like peptide-1 (GLP-1) or glucose-dependent insulinotropic polypeptide (GIP) agonists who continued their medication until…
Sacubitril/Valsartan Shows Promise in Reducing Nocturia in Hypertensive Patients, finds study
Japan: A pilot study published in Translational Andrology and Urology suggests that sacubitril/valsartan, a novel antihypertensive therapy, may help reduce nocturia in patients with hypertension. The findings point to a…
STAT+: Pharmalittle: We’re reading about TrumpRx prices, a J&J psoriasis pill, and much more
U.S. health officials claim TrumpRx offers Americans the world’s lowest prices on prescription drugs, but a new analysis found that is not true
STAT+: J&J wins approval for first-of-its-kind psoriasis pill
Johnson & Johnson won U.S. approval for a daily psoriasis pill that rivals the benefits of injectable medicines and could roil a multibillion-dollar market.
Health Bulletin 18/March/2026
Here are the top health stories for the day:NEET SS Counselling: MCC Withdraws 12 Super-Speciality Seats From Round One MatrixThe Medical Counselling Committee (MCC), under the Directorate General of Health…
HC Relief to Senior Hematologist, Pharmacologist in Disproportionate asset case
Cuttack: Citing a lack of prima facie evidence and an inordinate delay of over eight years in completing the investigation, the Orissa High Court has granted relief to two doctors…